Anti-herpetic treatment reduces dementia risk: A systematic review and meta-analysis
- 30 December 2025
- journal article
- review article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (4) , 1590-1602
Abstract
Background: Human herpesvirus (HHV) infections, particularly for herpes simplex virus (HSV) and varicella-zoster virus (VZV), may increase dementia risk, yet the protective effects of anti-herpetic medications remained unclear. Objective: This systematic review and meta-analysis of observational studies aimed to examine the association between anti-herpetic medications and dementia, focusing on HSV or VZV-related infections. Methods: This study followed PRISMA guidelines (CRD42022368318). Cohort or nested case-control studies published from databases’ inception to December 2024 were systematically searched in PubMed, MEDLINE, Embase, Cochrane Library, PsycINFO, and Web of Science. Eligible studies evaluated anti-herpetic medications (e.g., acyclovir, famciclovir, ganciclovir, valacyclovir, valganciclovir) and dementia risk in non-demented adults aged ≥50. Pooled adjusted hazard ratios (aHR) and 95% confidence intervals (CIs) were analyzed using random-effects models. Subgroup and meta-regression analyses were performed to explore potential sources of heterogeneity and effect modifiers. Results: Fourteen cohort studies involving more than 10 million older adults were included. To demonstrate the effects of anti-herpetic medications in various clinical scenarios, the meta-analysis compared: diagnosed and treated versus diagnosed but untreated (aHR=0.77, 95% CI: 0.67–0.89); treated versus untreated regardless of diagnosis (aHR=0.90, 95% CI: 0.87–0.94); and diagnosed and treated versus neither diagnosed nor treated (aHR=0.87, 95% CI: 0.78–0.97). Subgroup analysis and meta-regression identified infection severity as a significant modifier ( p < 0.0001), explaining 89.01% of heterogeneity. Conclusions: This systematic review and meta-analysis reveals notable protective effect of anti-herpetic medication usage on dementia, and the effect is especially pronounced in patients with severe alpha herpesvirus infections.Keywords
Funding Information
- Far Eastern Memorial Hospital-National Yang Ming University collaboration grant (110DN18)
This publication has 38 references indexed in Scilit:
- Herpes zoster vaccination and the risk of dementia: A systematic review and meta‐analysisBrain and Behavior, 2024
- The association between varicella zoster virus and dementia: a systematic review and meta-analysis of observational studiesNeurological Sciences, 2023
- No evidence that herpes zoster is associated with increased risk of dementia diagnosisAnnals of Clinical and Translational Neurology, 2022
- Symptomatic Herpes Simplex Virus Infection and Risk of Dementia in US Veterans: a Cohort StudyNeurotherapeutics, 2021
- Association of herpes zoster with dementia and effect of antiviral therapy on dementia: a population-based cohort studyEuropean Archives of Psychiatry and Clinical Neuroscience, 2020
- Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections—a Nationwide, Population-Based Cohort Study in TaiwanNeurotherapeutics, 2018
- Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2016
- Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cellsJournal of Neuroscience Research, 2012
- A basic introduction to fixed-effect and random-effects models for meta-analysisResearch Synthesis Methods, 2010
- Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaquesThe Journal of Pathology, 2008